Thyrogen.com -- Testing and Management of Well-Differentiated Thyroid Cancer

We have detected that your browser does not have Javascript turned on. This site is optimized for Javascript.
You may experience difficulties browsing certain parts of the site.

Genzyme Corporate

Research

Genzyme Websites

About Thyrogen

Testing and Management

	Management Guidelines
	Management Options
	Tg Testing
	Risk Staging

Ordering and Reimbursement

Resources

Prescribing Information (PDF)

Well-Differentiated Thyroid Cancer: Testing and Management

Although the survival rate is high, well-differentiated thyroid cancers account for about 75% of thyroid-cancer deaths.^[1] Because of this, lifelong monitoring is required for the management of well-differentiated cancers.^[1]

Several professional societies have developed sets of guidelines for the assessment, treatment, and lifelong management of thyroid cancer.

In this section you can:

Read about testing and management guidelines

Download a flow chart to help you with risk-stratification practices

Access a sample management algorithm

Read a leading expert’s views on the long-term follow-up of well-differentiated thyroid cancer

Reference

1. Robbins R, Drucker W, Hann L, Tuttle RM. Advances in the detection of residual thyroid carcinoma. In: Pellitteri P, ed. Endocrine Surgery of the Head and Neck. 1st ed. San Diego, California: Singular Publishing Group;2001:277-294.

Safety Information
Thyrogen® (thyrotropin alfa for injection) is indicated for use as an adjunctive diagnostic tool for serum thyroglobulin (Tg) testing with or without radioiodine whole-body scan (WBS) in the follow-up of patients with well-differentiated thyroid cancer. It is a prescription product injected into the muscle. Thyrogen® may not be appropriate for all patients. The most commonly reported adverse events are headache, nausea, weakness and vomiting. Even with a Thyrogen®-stimulated Tg testing and WBS, a risk remains of missing a diagnosis of thyroid cancer or of underestimating the extent of disease. Adverse events should be reported promptly to Genzyme Medical Information at 1-800-745-4447. For more information on Thyrogen®, please see full prescribing information (PDF), contact the Medical Information department or contact Genzyme toll free at 1-88-THYROGEN (1-888-497-6436).


	Search Thyrogen
	Keyword:
	Search In:

Highlight

	Consider the Facts: Thyroid Cancer is the most common endocrine cancer and occurs in all age groups. Thyroid Cancer recently was ranked as the #1 cancer in incidence growth in women (National Cancer Institute data). Thyroid Cancer may recur in up to 30% of patients, even decades after initial diagnosis.

	Resources

	Request Clinical Information Patient Education Materials Request Materials Reconstitution Guide Product Monograph Related Links Testing Schedule Tg Lab Tracking Form Events Calendar Publications


	Contact Information

	Genzyme Therapeutics 500 Kendall Street Cambridge, MA 02142 888 497 6436 617 768 8050

	Contact Genzyme